Crystalline Form of a 4-[2-(2-Fluorophenoxymethyl)PHENYL]PIPERIDINE Compound
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 61/114,541, filed Nov 14, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,226,454 | Crystalline Form of a 4-[2-(2-Fluorophenoxymethyl)PHENYL]PIPERIDINE Compound In force · Medium confidence | Theravance Biopharma R&D IP, LLC | In force | Medium confidence | ||
| US 11,596,624 | Crystalline Form of a 4-[2-(2-Fluorophenoxymethyl)PHENYL]PIPERIDINE Compound In force · Medium confidence | Theravance Biopharma R&D IP, LLC | In force | Medium confidence | ||
| US 8,304,433 | Crystalline Form of a 4-[2-(2-Fluorophenoxymethyl)PHENYL]PIPERIDINE Compound In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.